Clinical trial
Dalacin-T Gel Post Approval Study
NCT00219570 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00219570 |
|---|---|
| Title | Dalacin-T Gel Post Approval Study |
| Official title | Phase IV Clinical Study Of Clindamycin Phosphate Topical Gel In The Treatment Of Acne Vulgaris |
| Lead sponsor | Pfizer, Industry |
| Collaborators | Parexel Industry SACT INTERNATIONAL Co., LTD. Acronet Bellsystem24 , Inc. Mitsubishi Kagaku Bio-Clinical Laboratories, inc SATO Pharmaceutical Co., Ltd. |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Acne Vulgaris |
| Intervention type | Drug |
| Interventions | clindamycin, nadifloxacin |
| Enrollment | 134 |
| Start date | Jan 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Sep 22, 2005 |
| Last update posted | May 11, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: